Demand for weight loss drugs may fuel growth for more than one player.

Eli Lilly (NYSE:LLY | LLY Price Prediction) is growing like a software company. Q1 2026 revenue hit $19.80B, up 55.5% year ...

A lawsuit filed by the pharmaceutical giant alleges that Bishop Jerry Maynard Sr. and Elder Readus C. Smith III, a national ...

With construction starting soon on the massive Eli Lilly and Co. pharmaceutical plant in Upper Macungie Township, some are ...

After a stunning Q1 earnings report and raised full-year guidance, the question is whether the valuation has run ahead of ...

Eli Lilly announced clinical trial results for retatrutide, its next gen obesity drug. The drug helped study participants lose 70 lbs over 80 weeks, making it more powerful than Zepbound and Wegovy.

However, Eli Lilly launched its own weight loss pill, orforglipron, marketed as Foundayo, in April. And the company has ...

Lilly said people on the next-generation weight loss medication across three different dosages achieved weight loss of 19% to ...

Since announcing a transformational $250 million partnership in May 2025, Purdue University and Eli Lilly and Company have ...

In the rapidly expanding obesity treatment market, where Lilly competes with Novo Nordisk, the results were consistent with ...